ArticleFrontiers in immunology2022

PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.

Dan Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.